Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1141957

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what are the drugs approved by NICE to treat HER2+ breast cancer; and what assessment they have made of the efficacy of such drugs.
tabling member printed	Lord Willis of Knaresborough
uin	HL17501
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17502 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141958

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pertuzumab
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what advice they provide to clinicians for the use of Pertuzumab rather than Herceptin for the treatment of HER2+ breast cancer.
tabling member printed	Lord Willis of Knaresborough
uin	HL17502
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17501 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141255

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Non-surgical Cosmetic Procedures: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what legal duties govern the administering of dermal fillers to people under the age of 18 by non-regulated practitioners.
tabling member constituency	North Durham
tabling member printed	Mr Kevan Jones
uin	280927
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Currently there are no restrictions that limit the administration of dermal fillers on young people under the age of 18 years old.</p><p>The Department is exploring options to introduce age restrictions on access to cosmetic procedures, bringing them in line with legislation on tattoos, teeth whitening and the use of sunbeds. From May 2020 all dermal fillers, irrespective of their composition and intended use, will be regulated as medical devices under Annex XVI of the Medical Device Regulations (EU 2017/745). The new Regulations will significantly improve the quality and safety of dermal fillers.</p><p>The Government is committed to improving the safety of cosmetic procedures through better training for practitioners, and clear information so that people can make informed decisions about their care. The growth in non-surgical treatments increases the need for consumer protection and we are currently working with stakeholders to strengthen the regulation of cosmetic procedures.</p><p>We urge anyone seeking a cosmetic procedure to take the time to find a reputable, insured and appropriately qualified practitioner who is either subject to statutory regulation or on a voluntary register accredited by the Professional Standards Authority.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:32:36 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1438 label Biography information for Lord Beamish

1141380

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	MMR Vaccine: Safety
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain and improve pharmacovigilance in relation to the MMR vaccine.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	280998
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella (MMR) vaccine remains under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance, including regular review of suspected adverse reactions submitted through the Yellow Card Scheme, data from clinical and epidemiological studies, the medical literature and information from pharmaceutical companies and other worldwide regulatory authorities. The MHRA’s processes and data analysis systems are regularly evaluated to ensure optimal performance in monitoring the safety of vaccines and medicines.</p><p>The balance of benefits and risks of MMR vaccine remains overwhelmingly favourable.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:35:38 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1141381

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	MMR Vaccine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure (a) transparency and (b) accountability in the process of manufacturing the MMR vaccine.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	280999
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service’s routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro and Priorix have been evaluated before they were given a Marketing Authorisation in Europe, and the Marketing Authorisation Holder for each vaccines is legally required to submit periodic safety update reports to the regulator, which are documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation. The sites at which the products are manufactured are also required to undergo periodic inspections to ensure that they comply with Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer’s testing. These procedures ensure that the MMR vaccines available in the UK are safe and efficacious and that the manufacturers/Marketing Authorisation holders are held accountable for their products.</p><p>A European Public Assessment Report (EPAR) for M-M-RVaxPro is available at the following link:</p><p><a href="https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf" target="_blank">https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf</a></p><p>Priorix was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro contains a general summary of the manufacturing information that was provided during the assessment process; however, the specific details of the manufacturing process are confidential.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:38:57 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1141399

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Speech and Language Therapy: Children and Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the report of the Children's Commissioner entitled, We need to talk: Access to speech and language therapy, published in June 2019, what plans he has to ensure that expenditure data is collected on the support local areas provide for children and young people with speech, language and communication needs.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	281095
answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>The Department is keen to work with the Children’s Commissioner’s Office and other partners on options for producing expenditure data on speech, language and communication services. Officials will discuss this matter at the next available opportunity.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/07/2019 11:45:16 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4603 label Biography information for Preet Kaur Gill

1141438

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sepsis: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the implications for his policies of the recommendations of the All-Party Parliamentary Group on Sepsis Annual Report 2019; and if he will make a statement.
tabling member constituency	Neath
tabling member printed	Christina Rees
uin	281108
answer	answer is ministerial correction date of answer 29/07/2019 answer text <p>The United Kingdom’s five-year antimicrobial resistance (AMR) strategy, published in January 2019, includes the commitment to develop a real-time patient level data source of a patient’s infection, treatment and resistance history which will be used to inform their treatment and the development of interventions to tackle severe infection, sepsis and AMR. This commitment was reaffirmed in the open consultation ‘Advancing our health: prevention in the 2020s’, published by the Department and Cabinet Office on 22 July 2019.</p><p>Public Health England continues to raise awareness of the signs and symptoms of sepsis by building sepsis messaging into the national Start4life Information Service for Parents email programme which targets parents of zero to five-year olds. Any nationally supported campaigns must be aimed at appropriate audiences and deliver measurable outcomes. The Department looks to NHS England and NHS Improvement’s Cross-System Sepsis Programme Board, which brings together a group of front-line experts from across the health and care system including the UK Sepsis Trust, for advice on the best interventions to improve patient outcomes.</p><p>NHS England and NHS Improvement will consider other recommendations of the All-Party Parliamentary Group on Sepsis Annual Report 2019 in the context of its overall work on infection prevention.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 281111 281112 question first answered 29/07/2019 09:39:15 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4525 label Biography information for Christina Rees

1141441

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sepsis: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure better use of data interoperability to identify patients most at risk of sepsis.
tabling member constituency	Neath
tabling member printed	Christina Rees
uin	281111
answer	answer is ministerial correction date of answer 29/07/2019 answer text <p>The United Kingdom’s five-year antimicrobial resistance (AMR) strategy, published in January 2019, includes the commitment to develop a real-time patient level data source of a patient’s infection, treatment and resistance history which will be used to inform their treatment and the development of interventions to tackle severe infection, sepsis and AMR. This commitment was reaffirmed in the open consultation ‘Advancing our health: prevention in the 2020s’, published by the Department and Cabinet Office on 22 July 2019.</p><p>Public Health England continues to raise awareness of the signs and symptoms of sepsis by building sepsis messaging into the national Start4life Information Service for Parents email programme which targets parents of zero to five-year olds. Any nationally supported campaigns must be aimed at appropriate audiences and deliver measurable outcomes. The Department looks to NHS England and NHS Improvement’s Cross-System Sepsis Programme Board, which brings together a group of front-line experts from across the health and care system including the UK Sepsis Trust, for advice on the best interventions to improve patient outcomes.</p><p>NHS England and NHS Improvement will consider other recommendations of the All-Party Parliamentary Group on Sepsis Annual Report 2019 in the context of its overall work on infection prevention.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 281108 281112 question first answered 29/07/2019 09:39:16 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4525 label Biography information for Christina Rees

1141442

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sepsis: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the recommendations of the All-Party Parliamentary Group on Sepsis Annual Report 2019, if he will commit to commissioning a public awareness campaign on sepsis to (a) make more people aware of and (b) improve survival rates for people experiencing that condition.
tabling member constituency	Neath
tabling member printed	Christina Rees
uin	281112
answer	answer is ministerial correction date of answer 29/07/2019 answer text <p>The United Kingdom’s five-year antimicrobial resistance (AMR) strategy, published in January 2019, includes the commitment to develop a real-time patient level data source of a patient’s infection, treatment and resistance history which will be used to inform their treatment and the development of interventions to tackle severe infection, sepsis and AMR. This commitment was reaffirmed in the open consultation ‘Advancing our health: prevention in the 2020s’, published by the Department and Cabinet Office on 22 July 2019.</p><p>Public Health England continues to raise awareness of the signs and symptoms of sepsis by building sepsis messaging into the national Start4life Information Service for Parents email programme which targets parents of zero to five-year olds. Any nationally supported campaigns must be aimed at appropriate audiences and deliver measurable outcomes. The Department looks to NHS England and NHS Improvement’s Cross-System Sepsis Programme Board, which brings together a group of front-line experts from across the health and care system including the UK Sepsis Trust, for advice on the best interventions to improve patient outcomes.</p><p>NHS England and NHS Improvement will consider other recommendations of the All-Party Parliamentary Group on Sepsis Annual Report 2019 in the context of its overall work on infection prevention.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 281108 281111 question first answered 29/07/2019 09:39:16 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4525 label Biography information for Christina Rees

1141460

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to encourage health and wellbeing boards to measure and monitor children's subjective well-being as a key outcome in their local area.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	280948
answer	answer is ministerial correction date of answer 29/07/2019 answer text <p>Health and Wellbeing Boards in England bring into one forum representatives from health, social services and the local community to decide what the main public health needs of the local population are, and to determine how best to meet them in an integrated and holistic manner. Health and Wellbeing Boards are required to produce Joint Strategic Needs Assessment (JSNA) for their area. Based on the needs identified the Board produces a Joint Health and Wellbeing Strategy (JHWS). Both the JSNA and JHWS must be taken into account by local authorities, clinical commissioning groups and NHS England when preparing or revising commissioning.</p><p>We believe that local leaders are best placed to make decisions as to the need of the population they serve, including for children and young people’s wellbeing. Places such as Greater Manchester Combined Authority have produced a dedicated Children and Young People Health and Wellbeing Framework for 2018-2022.</p><p>As health is a devolved matter in Wales, it would therefore be the responsibility of the Welsh Government to decide how to monitor children’s wellbeing.</p><p> </p><p> </p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 29/07/2019 09:42:45 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	534 label Biography information for Chris Ruane